Results of adjuvant chemotherapy for invasive uroepithelial cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-01

AUTHORS

Yasunari Uekado, Atsuyuki Hirano, Toshiaki Shinka, Tadashi Ohkawa

ABSTRACT

Between June 1982 and July 1990, 55 patients (41 with bladder cancers and 14 with renal pelvic or ureteral cancers) who had undergone radical extirpative surgery and/or node dissection for pathological stage pT2-4 and/or nodal disease received adjuvant chemotherapy consisting of cisplatin alone or in combination with other agents. In all, 26 of the bladder-cancer patients also received preoperative chemotherapy consisting of arterial infusion of cisplatin, mitomycin C, and Adriamycin. Adjuvant chemotherapy was performed according to the following protocol. Between June 1982 and July 1987, 30-50 mg/m2 cisplatin either alone or in combination with Adriamycin and 5-fluorouracil (CAF) was given to 35 patients in an induction and maintenance setting for 1 year. After July 1987, short-course cisplatin (70 mg/m2) or cisplatin, etoposide, and Adriamycin combination chemotherapy (CVA) was given to 20 patients. Of the 55 patients, 38 are alive and show no evidence of disease, three are alive with disease, 13 have died of their disease, and 1 has died of an unrelated cause. The 5-year survival of all patients was 65.1%. The survival of the 20 patients who were treated after July 1987 was better than that of the 35 patients who were treated before June 1987. Local recurrence and/or distant dissemination occurred in 16 patients, 13 of whom died of cancer progression. Nausea and vomiting and anorexia occurred in most patients during the administration of cisplatin. Mild to moderate myelosuppression developed in patients who received CAF or CVA combination chemotherapy. Although adjuvant chemotherapy combined with radical surgery seemed to be effective in cases with a pathological stage of pT3a or less, more intensive pre- or postoperative chemotherapy is needed to improve the poor prognosis of patients with deeply invasive uroepithelial cancer. More... »

PAGES

s55-s58

References to SciGraph publications

  • 1987-08. Adjuvant chemotherapy for invasive bladder cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf00686943

    DOI

    http://dx.doi.org/10.1007/bf00686943

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1017502101

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/1394819


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemotherapy, Adjuvant", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cisplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Doxorubicin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Administration Schedule", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Etoposide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fluorouracil", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Infusions, Intra-Arterial", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mitomycin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ureteral Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Urinary Bladder Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Wakayama Medical University", 
              "id": "https://www.grid.ac/institutes/grid.412857.d", 
              "name": [
                "Department of Urology, Wakayama Medical College, 27, 7-ban-cho, Wakayama City, Wakayama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Uekado", 
            "givenName": "Yasunari", 
            "id": "sg:person.01220725701.94", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220725701.94"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Wakayama Medical University", 
              "id": "https://www.grid.ac/institutes/grid.412857.d", 
              "name": [
                "Department of Urology, Wakayama Medical College, 27, 7-ban-cho, Wakayama City, Wakayama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hirano", 
            "givenName": "Atsuyuki", 
            "id": "sg:person.01246440565.92", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246440565.92"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Wakayama Medical University", 
              "id": "https://www.grid.ac/institutes/grid.412857.d", 
              "name": [
                "Department of Urology, Wakayama Medical College, 27, 7-ban-cho, Wakayama City, Wakayama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shinka", 
            "givenName": "Toshiaki", 
            "id": "sg:person.01064076765.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064076765.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Wakayama Medical University", 
              "id": "https://www.grid.ac/institutes/grid.412857.d", 
              "name": [
                "Department of Urology, Wakayama Medical College, 27, 7-ban-cho, Wakayama City, Wakayama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ohkawa", 
            "givenName": "Tadashi", 
            "id": "sg:person.01225622541.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225622541.68"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007535582"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0090-4295(82)90601-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012745676"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0090-4295(85)90527-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016211520"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00262480", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027362480", 
              "https://doi.org/10.1007/bf00262480"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00262480", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027362480", 
              "https://doi.org/10.1007/bf00262480"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0090-4295(84)80080-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031449583"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/1097-0142(19900115)65:2<207::aid-cncr2820650204>3.0.co;2-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037698192"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0090-4295(85)90532-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041944249"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1080006783", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-5347(17)48996-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1080095427"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-5347(17)50459-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1081632879"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-5347(17)52202-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1081903165"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-5347(17)50809-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1081925328"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-5347(17)55143-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082229203"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082925820", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1992-01", 
        "datePublishedReg": "1992-01-01", 
        "description": "Between June 1982 and July 1990, 55 patients (41 with bladder cancers and 14 with renal pelvic or ureteral cancers) who had undergone radical extirpative surgery and/or node dissection for pathological stage pT2-4 and/or nodal disease received adjuvant chemotherapy consisting of cisplatin alone or in combination with other agents. In all, 26 of the bladder-cancer patients also received preoperative chemotherapy consisting of arterial infusion of cisplatin, mitomycin C, and Adriamycin. Adjuvant chemotherapy was performed according to the following protocol. Between June 1982 and July 1987, 30-50 mg/m2 cisplatin either alone or in combination with Adriamycin and 5-fluorouracil (CAF) was given to 35 patients in an induction and maintenance setting for 1 year. After July 1987, short-course cisplatin (70 mg/m2) or cisplatin, etoposide, and Adriamycin combination chemotherapy (CVA) was given to 20 patients. Of the 55 patients, 38 are alive and show no evidence of disease, three are alive with disease, 13 have died of their disease, and 1 has died of an unrelated cause. The 5-year survival of all patients was 65.1%. The survival of the 20 patients who were treated after July 1987 was better than that of the 35 patients who were treated before June 1987. Local recurrence and/or distant dissemination occurred in 16 patients, 13 of whom died of cancer progression. Nausea and vomiting and anorexia occurred in most patients during the administration of cisplatin. Mild to moderate myelosuppression developed in patients who received CAF or CVA combination chemotherapy. Although adjuvant chemotherapy combined with radical surgery seemed to be effective in cases with a pathological stage of pT3a or less, more intensive pre- or postoperative chemotherapy is needed to improve the poor prognosis of patients with deeply invasive uroepithelial cancer.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/bf00686943", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "Suppl 1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "30"
          }
        ], 
        "name": "Results of adjuvant chemotherapy for invasive uroepithelial cancer", 
        "pagination": "s55-s58", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "5362e80c117ac692c9507fa028a2eee3401c0721f27a75ac8f1acb68258158dd"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "1394819"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "7806519"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf00686943"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1017502101"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf00686943", 
          "https://app.dimensions.ai/details/publication/pub.1017502101"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T14:16", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117088_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007/BF00686943"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00686943'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00686943'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00686943'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00686943'


     

    This table displays all metadata directly associated to this object as RDF triples.

    211 TRIPLES      21 PREDICATES      63 URIs      41 LITERALS      29 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf00686943 schema:about N1449cd7252bc402c962347eb762c346f
    2 N18bd6eca30fe4d1bb5ea395ba4fb5e49
    3 N20070dffe1d84dbea32d31b6d39bbfc7
    4 N3199b4e638444f719ce55b124d3631ed
    5 N47826af132784f239fc5a049db4e1da6
    6 N485bcfdcd1e34b518df9dd15724b74f0
    7 N49e345180d674fcd9ae73d88d88e6a2a
    8 N5d2b207f55ac45919e37b048957f7fd6
    9 N628b623ee0f84b1c8671f2cf1ad79849
    10 N6e45ebb1a487496caeeac428b7357f75
    11 N7a774916ba8d4221b5544bebeff3746b
    12 N8324fbe6ae8646b38f1ca3f8e57b94b1
    13 N8afe9b1297674f2080cace723db50183
    14 N8ef4e1c74db74b4189b1a8a30b1b7d85
    15 Na685920e9e6346fea07baa01a6cccffc
    16 Na7a7300476484caaab2c4d9fe2b7a93f
    17 Na87b6bf83dda4848b7a0c79b99c75c81
    18 Nda4889c6eada4cdfabb76853c9a3f7c2
    19 Ne184a5f8851740eb8ddd8b62dfa2e9a2
    20 Ne8d02e4a83164eeb99c8f56cbacd993f
    21 anzsrc-for:11
    22 anzsrc-for:1112
    23 schema:author N904331ea3c8542409493c3c8d35fdd97
    24 schema:citation sg:pub.10.1007/bf00262480
    25 https://app.dimensions.ai/details/publication/pub.1080006783
    26 https://app.dimensions.ai/details/publication/pub.1082925820
    27 https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7
    28 https://doi.org/10.1002/1097-0142(19900115)65:2<207::aid-cncr2820650204>3.0.co;2-2
    29 https://doi.org/10.1016/0090-4295(82)90601-x
    30 https://doi.org/10.1016/0090-4295(85)90527-8
    31 https://doi.org/10.1016/0090-4295(85)90532-1
    32 https://doi.org/10.1016/s0022-5347(17)48996-8
    33 https://doi.org/10.1016/s0022-5347(17)50459-0
    34 https://doi.org/10.1016/s0022-5347(17)50809-5
    35 https://doi.org/10.1016/s0022-5347(17)52202-8
    36 https://doi.org/10.1016/s0022-5347(17)55143-5
    37 https://doi.org/10.1016/s0090-4295(84)80080-1
    38 schema:datePublished 1992-01
    39 schema:datePublishedReg 1992-01-01
    40 schema:description Between June 1982 and July 1990, 55 patients (41 with bladder cancers and 14 with renal pelvic or ureteral cancers) who had undergone radical extirpative surgery and/or node dissection for pathological stage pT2-4 and/or nodal disease received adjuvant chemotherapy consisting of cisplatin alone or in combination with other agents. In all, 26 of the bladder-cancer patients also received preoperative chemotherapy consisting of arterial infusion of cisplatin, mitomycin C, and Adriamycin. Adjuvant chemotherapy was performed according to the following protocol. Between June 1982 and July 1987, 30-50 mg/m2 cisplatin either alone or in combination with Adriamycin and 5-fluorouracil (CAF) was given to 35 patients in an induction and maintenance setting for 1 year. After July 1987, short-course cisplatin (70 mg/m2) or cisplatin, etoposide, and Adriamycin combination chemotherapy (CVA) was given to 20 patients. Of the 55 patients, 38 are alive and show no evidence of disease, three are alive with disease, 13 have died of their disease, and 1 has died of an unrelated cause. The 5-year survival of all patients was 65.1%. The survival of the 20 patients who were treated after July 1987 was better than that of the 35 patients who were treated before June 1987. Local recurrence and/or distant dissemination occurred in 16 patients, 13 of whom died of cancer progression. Nausea and vomiting and anorexia occurred in most patients during the administration of cisplatin. Mild to moderate myelosuppression developed in patients who received CAF or CVA combination chemotherapy. Although adjuvant chemotherapy combined with radical surgery seemed to be effective in cases with a pathological stage of pT3a or less, more intensive pre- or postoperative chemotherapy is needed to improve the poor prognosis of patients with deeply invasive uroepithelial cancer.
    41 schema:genre research_article
    42 schema:inLanguage en
    43 schema:isAccessibleForFree false
    44 schema:isPartOf N4b88bcbce57b48ecaeb73029ac928c94
    45 N68e1b9ded57e4666a6e9732a25a8f968
    46 sg:journal.1088364
    47 schema:name Results of adjuvant chemotherapy for invasive uroepithelial cancer
    48 schema:pagination s55-s58
    49 schema:productId N0da016f7173f46529ccd989c66ddeafc
    50 N453d37219b424fde8c67756ff709971c
    51 N89e1432524b94ba98207bb47385bfcfc
    52 Nb4e5bbe02102405c80e9b4fa970cb586
    53 Nbc6d6b9f1a334afa99ba9925fc6cd7bc
    54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017502101
    55 https://doi.org/10.1007/bf00686943
    56 schema:sdDatePublished 2019-04-11T14:16
    57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    58 schema:sdPublisher N717ec88bceda47f483580832c5b50de4
    59 schema:url http://link.springer.com/10.1007/BF00686943
    60 sgo:license sg:explorer/license/
    61 sgo:sdDataset articles
    62 rdf:type schema:ScholarlyArticle
    63 N0da016f7173f46529ccd989c66ddeafc schema:name doi
    64 schema:value 10.1007/bf00686943
    65 rdf:type schema:PropertyValue
    66 N1258fb616bff406e9abbdd6de1243170 rdf:first sg:person.01064076765.62
    67 rdf:rest N4628bf8a7866496eb93259c15bfd4856
    68 N1449cd7252bc402c962347eb762c346f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    69 schema:name Male
    70 rdf:type schema:DefinedTerm
    71 N18bd6eca30fe4d1bb5ea395ba4fb5e49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    72 schema:name Kidney Neoplasms
    73 rdf:type schema:DefinedTerm
    74 N20070dffe1d84dbea32d31b6d39bbfc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    75 schema:name Aged, 80 and over
    76 rdf:type schema:DefinedTerm
    77 N3199b4e638444f719ce55b124d3631ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    78 schema:name Ureteral Neoplasms
    79 rdf:type schema:DefinedTerm
    80 N453d37219b424fde8c67756ff709971c schema:name nlm_unique_id
    81 schema:value 7806519
    82 rdf:type schema:PropertyValue
    83 N4628bf8a7866496eb93259c15bfd4856 rdf:first sg:person.01225622541.68
    84 rdf:rest rdf:nil
    85 N47826af132784f239fc5a049db4e1da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Antineoplastic Combined Chemotherapy Protocols
    87 rdf:type schema:DefinedTerm
    88 N485bcfdcd1e34b518df9dd15724b74f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name Etoposide
    90 rdf:type schema:DefinedTerm
    91 N49e345180d674fcd9ae73d88d88e6a2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Fluorouracil
    93 rdf:type schema:DefinedTerm
    94 N4b88bcbce57b48ecaeb73029ac928c94 schema:volumeNumber 30
    95 rdf:type schema:PublicationVolume
    96 N5d2b207f55ac45919e37b048957f7fd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Mitomycin
    98 rdf:type schema:DefinedTerm
    99 N628b623ee0f84b1c8671f2cf1ad79849 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Cisplatin
    101 rdf:type schema:DefinedTerm
    102 N68e1b9ded57e4666a6e9732a25a8f968 schema:issueNumber Suppl 1
    103 rdf:type schema:PublicationIssue
    104 N6e45ebb1a487496caeeac428b7357f75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Urinary Bladder Neoplasms
    106 rdf:type schema:DefinedTerm
    107 N717ec88bceda47f483580832c5b50de4 schema:name Springer Nature - SN SciGraph project
    108 rdf:type schema:Organization
    109 N7a774916ba8d4221b5544bebeff3746b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Humans
    111 rdf:type schema:DefinedTerm
    112 N8324fbe6ae8646b38f1ca3f8e57b94b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Chemotherapy, Adjuvant
    114 rdf:type schema:DefinedTerm
    115 N86b4a66616fa4679b01ab5a32e751f0d rdf:first sg:person.01246440565.92
    116 rdf:rest N1258fb616bff406e9abbdd6de1243170
    117 N89e1432524b94ba98207bb47385bfcfc schema:name dimensions_id
    118 schema:value pub.1017502101
    119 rdf:type schema:PropertyValue
    120 N8afe9b1297674f2080cace723db50183 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Drug Administration Schedule
    122 rdf:type schema:DefinedTerm
    123 N8ef4e1c74db74b4189b1a8a30b1b7d85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Survival Rate
    125 rdf:type schema:DefinedTerm
    126 N904331ea3c8542409493c3c8d35fdd97 rdf:first sg:person.01220725701.94
    127 rdf:rest N86b4a66616fa4679b01ab5a32e751f0d
    128 Na685920e9e6346fea07baa01a6cccffc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Infusions, Intra-Arterial
    130 rdf:type schema:DefinedTerm
    131 Na7a7300476484caaab2c4d9fe2b7a93f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Middle Aged
    133 rdf:type schema:DefinedTerm
    134 Na87b6bf83dda4848b7a0c79b99c75c81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Neoplasm Recurrence, Local
    136 rdf:type schema:DefinedTerm
    137 Nb4e5bbe02102405c80e9b4fa970cb586 schema:name readcube_id
    138 schema:value 5362e80c117ac692c9507fa028a2eee3401c0721f27a75ac8f1acb68258158dd
    139 rdf:type schema:PropertyValue
    140 Nbc6d6b9f1a334afa99ba9925fc6cd7bc schema:name pubmed_id
    141 schema:value 1394819
    142 rdf:type schema:PropertyValue
    143 Nda4889c6eada4cdfabb76853c9a3f7c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Aged
    145 rdf:type schema:DefinedTerm
    146 Ne184a5f8851740eb8ddd8b62dfa2e9a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Doxorubicin
    148 rdf:type schema:DefinedTerm
    149 Ne8d02e4a83164eeb99c8f56cbacd993f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Female
    151 rdf:type schema:DefinedTerm
    152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Medical and Health Sciences
    154 rdf:type schema:DefinedTerm
    155 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Oncology and Carcinogenesis
    157 rdf:type schema:DefinedTerm
    158 sg:journal.1088364 schema:issn 0344-5704
    159 1432-0843
    160 schema:name Cancer Chemotherapy and Pharmacology
    161 rdf:type schema:Periodical
    162 sg:person.01064076765.62 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
    163 schema:familyName Shinka
    164 schema:givenName Toshiaki
    165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064076765.62
    166 rdf:type schema:Person
    167 sg:person.01220725701.94 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
    168 schema:familyName Uekado
    169 schema:givenName Yasunari
    170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220725701.94
    171 rdf:type schema:Person
    172 sg:person.01225622541.68 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
    173 schema:familyName Ohkawa
    174 schema:givenName Tadashi
    175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225622541.68
    176 rdf:type schema:Person
    177 sg:person.01246440565.92 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
    178 schema:familyName Hirano
    179 schema:givenName Atsuyuki
    180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246440565.92
    181 rdf:type schema:Person
    182 sg:pub.10.1007/bf00262480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027362480
    183 https://doi.org/10.1007/bf00262480
    184 rdf:type schema:CreativeWork
    185 https://app.dimensions.ai/details/publication/pub.1080006783 schema:CreativeWork
    186 https://app.dimensions.ai/details/publication/pub.1082925820 schema:CreativeWork
    187 https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007535582
    188 rdf:type schema:CreativeWork
    189 https://doi.org/10.1002/1097-0142(19900115)65:2<207::aid-cncr2820650204>3.0.co;2-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037698192
    190 rdf:type schema:CreativeWork
    191 https://doi.org/10.1016/0090-4295(82)90601-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012745676
    192 rdf:type schema:CreativeWork
    193 https://doi.org/10.1016/0090-4295(85)90527-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016211520
    194 rdf:type schema:CreativeWork
    195 https://doi.org/10.1016/0090-4295(85)90532-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041944249
    196 rdf:type schema:CreativeWork
    197 https://doi.org/10.1016/s0022-5347(17)48996-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1080095427
    198 rdf:type schema:CreativeWork
    199 https://doi.org/10.1016/s0022-5347(17)50459-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081632879
    200 rdf:type schema:CreativeWork
    201 https://doi.org/10.1016/s0022-5347(17)50809-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081925328
    202 rdf:type schema:CreativeWork
    203 https://doi.org/10.1016/s0022-5347(17)52202-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081903165
    204 rdf:type schema:CreativeWork
    205 https://doi.org/10.1016/s0022-5347(17)55143-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082229203
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1016/s0090-4295(84)80080-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031449583
    208 rdf:type schema:CreativeWork
    209 https://www.grid.ac/institutes/grid.412857.d schema:alternateName Wakayama Medical University
    210 schema:name Department of Urology, Wakayama Medical College, 27, 7-ban-cho, Wakayama City, Wakayama, Japan
    211 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...